This post was originally published on this site

Equities analysts predict that Tilray Inc (NASDAQ:TLRY) will announce ($0.14) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Seven analysts have issued estimates for Tilray’s earnings, with estimates ranging from ($0.19) to ($0.09). Tilray posted earnings of ($0.62) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 77.4%. The company is scheduled to announce its next earnings results on Monday, March 1st.

According to Zacks, analysts expect that Tilray will report full-year earnings of ($2.39) per share for the current fiscal year, with EPS estimates ranging from ($2.55) to ($2.22). For the next year, analysts expect that the business will post earnings of ($0.47) per share, with EPS estimates ranging from ($0.79) to ($0.28). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow Tilray.

Tilray (NASDAQ:TLRY) last issued its earnings results on Monday, November 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.19. Tilray had a negative net margin of 242.60% and a negative return on equity of 92.70%. The firm had revenue of $51.41 million during the quarter, compared to analysts’ expectations of $54.91 million. During the same quarter last year, the company posted ($0.36) earnings per share. The firm’s revenue was up .6% compared to the same quarter last year.

TLRY has been the topic of a number of recent research reports. Stifel Nicolaus upgraded Tilray from a “sell” rating to a “hold” rating in a research note on Thursday, December 17th. Jefferies Financial Group cut shares of Tilray from a “hold” rating to an “underperform” rating and dropped their price objective for the stock from $5.60 to $4.77 in a research note on Monday, November 16th. Zacks Investment Research lowered shares of Tilray from a “buy” rating to a “hold” rating in a report on Friday, February 5th. Finally, Cantor Fitzgerald increased their price target on shares of Tilray from $11.00 to $24.20 and gave the stock a “neutral” rating in a report on Friday, January 15th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has assigned a buy rating to the stock. Tilray has an average rating of “Hold” and an average price target of $13.52.

TLRY traded up $21.56 during midday trading on Friday, hitting $63.91. 169,709,981 shares of the company were exchanged, compared to its average volume of 48,794,297. The company’s 50 day simple moving average is $16.21 and its 200 day simple moving average is $9.17. The firm has a market capitalization of $8.53 billion, a price-to-earnings ratio of -14.08 and a beta of 3.12. Tilray has a 1-year low of $2.43 and a 1-year high of $67.00. The company has a current ratio of 2.28, a quick ratio of 1.61 and a debt-to-equity ratio of 2.75.

Hedge funds and other institutional investors have recently modified their holdings of the company. Sanders Morris Harris LLC acquired a new position in Tilray during the fourth quarter worth about $124,000. Cubist Systematic Strategies LLC purchased a new position in Tilray in the 3rd quarter worth approximately $195,000. Iron Financial LLC acquired a new position in shares of Tilray during the 4th quarter worth approximately $192,000. Nuveen Asset Management LLC purchased a new stake in shares of Tilray in the second quarter valued at approximately $92,000. Finally, National Asset Management Inc. increased its holdings in shares of Tilray by 87.7% in the third quarter. National Asset Management Inc. now owns 19,090 shares of the company’s stock valued at $93,000 after purchasing an additional 8,920 shares during the last quarter. Institutional investors and hedge funds own 12.62% of the company’s stock.

About Tilray

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.

Read More: How dollar cost averaging works

Get a free copy of the Zacks research report on Tilray (TLRY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tilray Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Tilray and related companies with MarketBeat.com’s FREE daily email newsletter.